New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export SCTX’s income statement to Excel — free account
Scribe Therapeutics Inc.
SCTXScribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.
12.07
1.15
−8.70%
After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.
Follow SCTX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+2 more quarters Free account |
— | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 1.84 | 1.84 | 10.31 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (4.75) | (4.75) | (23.72) | |
P/B ratio |
— | 0.00 | 0.00 | 2.13 | |
Price to Tangible BV |
— | 0.00 | 0.00 | 2.13 | |
EV/Sales |
— | 0.36 | 0.36 | 3.58 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | 0.00 | 0.00 | 0.00 | |
EV/FCF |
— | 0.00 | 0.00 | 0.00 | |
Quick Ratio |
0.94 | — | 0.56 | 4.62 | |
Current Ratio |
0.97 | — | 0.57 | 4.72 | |
Net Debt/EBITDA |
— | — | 4.58 | 17.26 | |
Debt/Assets |
0.00% | — | 0.00% | 0.00% | |
Debt/Equity |
0.00 | — | 0.00 | 0.00 | |
Operating CF/Net income |
— | — | — | 1.14 | |
Capex/Depreciation |
— | — | — | (0.02) | |
Interest Coverage |
— | — | (34.04) | — | |
Research and Development Expense of Revenue |
— | — | 460.01% | 504.83% | |
Selling, General and Administrative Expense of Revenue |
— | — | 129.82% | 259.11% | |
Intangible Assets out of Total Assets |
0.00 | — | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | — | — | 74.27% | |
Graham Net Nets |
— | (1.07) | (1.07) | 0.44 | |
Graham Number |
— | 0.00 | 140.31 | 0.00 | |
Earnings Yield |
— | (60.70%) | (60.70%) | (52.93%) | |
Free Cash Flow Yield |
— | 0.00% | 0.00% | 0.00% | |
Revenue per Share |
— | 0.91 | 0.77 | 0.11 | |
Operating CF per Share |
— | — | — | (0.78) | |
Capex per Share |
— | — | — | 0.00 | |
Free Cash Flow per Share |
— | — | — | (0.78) | |
Cash per Share |
— | — | 17.37 | 12.02 | |
Shareholders Equity per Share |
— | — | (17.97) | 8.63 | |
Interest Debt per Share |
— | — | 0.00 | 0.00 | |
Book value per Share |
— | — | (17.97) | 8.63 | |
Free Cash Flow |
— | — | — | (11.26) | |
Working Capital |
(2.12) | — | (33.59) | 140.96 | |
Capital Expenditures |
— | — | — | (0.01) | |
Net Current Asset Value |
(34.35) | — | (57.31) | 116.13 | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.01 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated Nov 18, 2026